Vyriad

Vyriad company information, Employees & Contact Information

Explore related pages

Related company profiles:

At Vyriad, we are developing the next generation of targeted genetic therapies by engineering viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells. This targeting technology facilitates oncolytic virotherapy, in vivo gene therapies and gene editing applications. We are testing our oncolytic viruses as monotherapies and in combination with immuno-oncology drugs. Phase 1-2 Clinical Studies are currently active in: Non-small cell lung cancer Squamous cell carcinoma of the head and neck Metastatic colorectal cancer Breast cancer Bladder cancer Other cancer types Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, and other leading research and medical institutions.

Company Details

Employees
50
Founded
-
Address
Rochester, Mn 55901, Us
Phone
507-289-0944
Email
in****@****iad.com
Industry
Biotechnology
Website
vyriad.com
HQ
Rochester, MN
Looking for a particular Vyriad employee's phone or email?

Vyriad Questions

News

Vyriad and Weizmann Institute of Science Enter Exclusive License Agreement for In Vivo Gene Delivery Technology - Business Wire

Vyriad and Weizmann Institute of Science Enter Exclusive License Agreement for In Vivo Gene Delivery Technology Business Wire

Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies - PR Newswire

Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies PR Newswire

Novartis taps Vyriad for in vivo CAR-T cell therapy pact - FirstWord Pharma

Novartis taps Vyriad for in vivo CAR-T cell therapy pact FirstWord Pharma

Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing - Fierce Biotech

Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing Fierce Biotech

Vyriad signs 'huge' deal with Novartis to develop new cancer treatments - Post Bulletin

Vyriad signs 'huge' deal with Novartis to develop new cancer treatments Post Bulletin

Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur - PR Newswire

Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur PR Newswire

IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers - medRxiv

IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers medRxiv

The in vivo revolution: How Interius, Umoja, and Vyriad are transforming CAR-T cell therapy - Labiotech.eu

The in vivo revolution: How Interius, Umoja, and Vyriad are transforming CAR-T cell therapy Labiotech.eu

Cancer-killing virus designer Vyriad raises $24.4 million - The Business Journals

Cancer-killing virus designer Vyriad raises $24.4 million The Business Journals

Vyriad’s Cancer-Fighting Viruses to Get First Clinical Trial Against Solid Tumors - Twin Cities Business

Vyriad’s Cancer-Fighting Viruses to Get First Clinical Trial Against Solid Tumors Twin Cities Business

Vyriad Expands Phase 1 Trial to Test Voyager-V1 in Combination with Bavencio for Colorectal Cancer - Immuno-Oncology News

Vyriad Expands Phase 1 Trial to Test Voyager-V1 in Combination with Bavencio for Colorectal Cancer Immuno-Oncology News

Rochester's Vyriad lands a new $29.5 million round of investment - Post Bulletin

Rochester's Vyriad lands a new $29.5 million round of investment Post Bulletin

Vyriad Announces Oral Presentation at the 27th American Society of Gene & Cell Therapy Annual Meeting - PR Newswire

Vyriad Announces Oral Presentation at the 27th American Society of Gene & Cell Therapy Annual Meeting PR Newswire

Rochester Bio-Tech Firm Expanding at IBM Complex - KROC-AM

Rochester Bio-Tech Firm Expanding at IBM Complex KROC-AM

Mayo Clinic Biotech Spin-Off Vyriad Raising $9M for Expansion, Clinical Trials - Twin Cities Business

Mayo Clinic Biotech Spin-Off Vyriad Raising $9M for Expansion, Clinical Trials Twin Cities Business

Today's Headlines: Rochester's Vyriad is taking its shot at cancer - Post Bulletin

Today's Headlines: Rochester's Vyriad is taking its shot at cancer Post Bulletin

The List: Startup Founders with Corporate Training - Twin Cities Business

The List: Startup Founders with Corporate Training Twin Cities Business

Top Vyriad Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant